SGLT2 inhibitor

SGLT2 inhibitors began as diabetes pills that make the kidneys pour excess sugar into the urine, but they turned out to be powerful heart and kidney protectors too — a happy surprise that reshaped heart-failure care. Their generic names end in “-flozin.”

In the kidney they block a transporter called SGLT2 that normally reabsorbs glucose and sodium back into the blood. Blocking it sends sugar, sodium, and water out in the urine, which gently lowers blood sugar, blood pressure, and fluid load, though the full reason they help the heart is still being worked out.

Large trials showed they reduce hospitalizations and deaths in heart failure — across both the weak-pump and preserved-pump types — and slow the decline of failing kidneys, benefits seen even in people without diabetes. They have quickly become a core, guideline-recommended heart-failure therapy.

They are generally well tolerated, with the main cautions being genital yeast infections, mild dehydration, and a rare condition called euglycemic diabetic ketoacidosis, where ketoacidosis occurs without the very high blood sugar usually expected.